PDS Biotechnology Corporation 与 Merck KGaA 签署 Versamune™全球授权协议
印第安纳州 LAWRENCEBURG 2012年7月9日电 /美通社亚洲/ -- PDS Biotechnology Corporation 今天宣布,该公司已经与位于德国达姆施塔的 Merck KGaA 达成了全球独家授权协议,将 PDS Biotechnology 的新型 Versamune™ 纳米技术平台用于 Merck 目前正处临床前开发阶段的两项研究抗原特异性癌症免疫疗法。也就是说,Merck 获得了在其目前正处临床前开发阶段的两项研究抗原特异性癌症免疫疗法中使用该技术的权利。
PDS Biotechnology Corporation 将获得现金首付(金额未公布)、开发里程碑付款以及推广和销售里程碑付款。PDS Biotechnology Corporation 还将根据采用该技术的产品的销售额获得相应权利金。
根据该授权协议,PDS Biotechnology Corporation 将获得现金首付(金额未公布)、开发里程碑付款以及推广和销售里程碑付款。PDS Biotechnology Corporation 还将根据采用该技术的产品的销售额获得相应权利金。
PDS Biotechnology Corporation 首席执行官 Frank Bedu-Addo 博士表示:“我们非常高兴在癌症免疫疗法临床开发领域拥有丰富经验的 Merck 选择使用 Versamune™ 技术。PDS Biotechnology Corporation的业务战略是专注于一些有关临床前或早期临床阶段的战略性对外授权或合作交易,因此这笔交易对本公司来说非常重要。在该领域,各企业都将希望利用在癌症和传染病治疗和预防临床研究领域有着广泛应用前景的新技术来提升他们的产品线。”
PDS Biotechnology Corporation 和 Versamune™ 简介
PDS Biotechnology Corporation 是一家非上市生物技术公司,致力于通过利用带阳电荷的特殊合成脂质中新发现的属性来推广新一代免疫疗法和疫苗。专有的 Versamune™ 平台纳米技术,一旦与具体癌症相关的分子相结合,经证实与临床前癌症模式中的领先临床辅助治疗相比,可实现更高的肿瘤衰退率(Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530)。Versamune™ 纳米技术在开发新一代免疫疗法方面实现了巨大了进步。PDS Biotechnology Corporation 正在开发治疗子宫癌、头颈癌和黑瘤等多发癌症的主打产品。该技术还被用于开发预防流行病的疫苗。垂询有关 Versamune™ 和正在开发的产品的详情,请访问:www.pdsbiotech.com
消息来源: PDS Biotechnology Corporation
PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™
LAWRENCEBURG, Ind., July 9, 2012 /PRNewswire/ -- PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune™ nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development. Merck obtains the rights to utilize the technology with two investigational antigen-specific cancer immunotherapies which are in pre-clinical development.
Under the terms of the licensing agreement, PDS Biotechnology Corporation will receive an undisclosed upfront payment in cash, as well as development milestone payments, and commercial and sales milestone payments. PDS Biotechnology Corporation will also receive royalties on sales of the products incorporating the technology.
Dr. Frank Bedu-Addo, Chief Executive of PDS Biotechnology Corporation said, "We are very pleased that Merck which is experienced in the clinical development of cancer immunotherapies would like to utilize the Versamune™ technology. For PDS Biotechnology Corporation, this deal is important since the company's business strategy is focused on a few strategic out-licensing or partnering deals at a preclinical or early clinical stage. This is the stage where companies will be seeking to enhance their pipelines by taking advantage of a new technology that has broad potential applications in clinical research into the treatment and prevention of cancer and infectious diseases."
About PDS Biotechnology Corporation and Versamune™
PDS Biotechnology Corporation is a privately held biotechnology company founded to exploit the newly discovered properties of specific synthetic positively charged (cationic) lipids to commercialize a new generation of immunotherapies and vaccines. The proprietary Versamune™ platform nanotechnology, when combined with specific cancer-associated molecules, has been demonstrated to lead to increased tumor regression rates compared to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530). The Versamune™ nanotechnology presents a giant step forward in the development of the next generation of immunotherapies. PDS Biotechnology Corporation's lead products are being developed to treat prevalent cancers such as cervical cancer, head and neck cancer and melanoma. The technology is also being applied to the development of vaccines which are designed to protect against pandemic diseases. Visit www.pdsbiotech.com for more information on Versamune™ and products in development.
SOURCE PDS Biotechnology Corporation
Back to top
RELATED LINKS
http://www.pdsbiotech.com